Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Item
http://www.wikidata.org/entity/Q37602657
Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinomaInhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significanceMaximising the potential of AKT inhibitors as anti-cancer treatmentsSelective anti-cancer agents as anti-aging drugsPerifosine as a potential novel anti-telomerase therapy.Candidate cancer-targeting agents identified by expression-profiling arrays.Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.Progress of molecular targeted therapies for advanced renal cell carcinoma.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.Design, synthesis, biological evaluation, and molecular docking of novel benzopyran and phenylpyrazole derivatives as Akt inhibitors.Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Strategies to overcome therapeutic resistance in renal cell carcinoma.A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies.PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?
P2860

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Item
http://www.wikidata.org/entity/Q37602657
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Two phase 2 trials of the nove ...... rowth factor-targeted therapy.
@en
Two phase 2 trials of the nove ...... rowth factor-targeted therapy.
@nl
type
label
Two phase 2 trials of the nove ...... rowth factor-targeted therapy.
@en
Two phase 2 trials of the nove ...... rowth factor-targeted therapy.
@nl
prefLabel
Two phase 2 trials of the nove ...... rowth factor-targeted therapy.
@en
Two phase 2 trials of the nove ...... rowth factor-targeted therapy.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Two phase 2 trials of the nove ...... rowth factor-targeted therapy.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932